TERAPI ADJUVAN N-ASETILSISTEIN DALAM MEMPERBAIKI NILAI SCORS PASIEN SKIZOFRENIA
Abstract
Latar Belakang: Tahun 2019, WHO menggolongkan skizofrenia sebagai 10 penyakit teratas beban kesehatan secara global. Skizofrenia merupakan gangguan mental jangka panjang dengan gejala halusinasi, delusi, dan perubahan perilaku. Semakin buruknya prognosis skizofrenia disebabkan 98 % masalah gangguan kognitif yang dapat diukur dengan alat The Schizophrenia Cognition Rating Scale (ScoRS). Terapi baru dengan N-acetylsistein (NAC) dapat mempengaruhi glutamatergenik pada gangguan mental sehingga mempenagruhi nilai ScoRS.
Tujuan: Penelitian ini bertujuan mengetahui efektifitas terapi Adjuvan N-Asetilsistein dalam memperbaiki ScoRS pasien Skizofrenia di RSJD Surakarta.
Metode: Metode penelitan adalah Quasy Eksperimen single blind, pretest–posttest design. Populasi sebanyak 37 orang. Sampel perlakuan 17 responden dan sampel kontrol 17 responden dengan teknik purposive sampling. Dari hasil uji normalitas Kolmogorov Smirnov didapat data tidak berdistribusi normal sehingga uji bivariate menggunakan uji wilcoxon.
Hasil: Hasil analisa univariat didapati rerata ScoRS pretest kelompok kontrol 2,87 sedangkan kelompok intervensi 3,49. Rerata ScoRS posttest kelompok kontrol 1,47 dan kelompok intervensi 2,89. Rerata Penurunan ScoRS kelompok control 1,40 dan kelompok intervensi 0,59. Hasil analisa bivariate dengan p-value 0,001.
Simpulan: Dapat disimpulkan terdapat efektifitas terapi ajuvan N-asetilsistein dalam memperbaiki nilai SCoRS pasien skizofrenia. Disarankan terapi adjuvant NAC dapat dijadikan sebagai alternatf pengobatan skizofrenia sehingga kasus kejadian skizofrenia semakin menurun dimasa yang akan datang.
Full Text:
PDF (Bahasa Indonesia)References
WHO, “Schizophrenia,” WHO, 2019. https://www.who.int/news-room/fact-sheets/detail/schizophrenia.
B. L. K. RI, Hasil Utama Riskesdas 2018. Kementerian Kesehatan RI.
2020 Rekam Medis RSJD Arif Zainudin, Kasus Skizofrenia. 2020.
S. Idaiani, I. Yunita, D. H. Tjandrarini, L. Indrawati, I. Darmayanti, and N. Kusumawardani, “Prevalensi Psikosis di Indonesia berdasarkan Riset Kesehatan Dasar The Prevalence of Psychosis in Indonesia based on Basic Health Research,” vol. 3, no. 1, pp. 9–16, 2019, doi: https://doi.org/10.22435/jpppk.v3i1.1882.
K. K. RI, “Situai Kesehatan Jiwa di Indonesia,” in InfoDatin Pusat Data dan Informasi Kementerian Kesehatan RI, Kementerian Kesehatan RI, 2018, p. 2.
S. Grover and N. Malhotra, “Depression in elderly : A review of Indian research,” J. Geriatr. Ment. Heal., vol. 2, no. 1, pp. 4–15, 2015, doi: 10.4103/2348-9995.161376.
P. Gupta, M. Geniza, S. Naithani, J. L. Phillips, and E. Haq, “Chia ( Salvia hispanica ) Gene Expression Atlas Elucidates Dynamic Spatio-Temporal Changes Associated With Plant Growth and Development,” Front. Plants Sci., vol. 12, no. July, pp. 1–16, 2021, doi: 10.3389/fpls.2021.667678.
M. Rapado-Castro et al., “Cognitive effects of adjunctive N-acetyl cysteine in psychosis,” Natl. Lbrary Med., vol. 47, no. 5, pp. 866–876, 2016, doi: https://doi.org/10.1017/S0033291716002932.
M. Berk, Gin S Malhi, Laura J Gray, and Olivia M Dean, “The promise of N-acetylcysteine in neuropsychiatry. Trends in Pharmacological Sciences,” Trends Pharmacol. Sci., vol. 34, no. 3, pp. 167–77, 2013, doi: https://doi.org/10.1016/j.tips.2013.01.001.
Oliver D. Robertson, Nieves G. Coronado, Rickinder Sethi, Michael Berk, and Seetal Dodd, “Putative neuroprotective pharmacotherapies to target the staged progression of mental illness,” Early Interv. Psychiatry, vol. 13, no. 5, pp. 1032–1049, 2019, doi: https://doi.org/10.1111/eip.12775.
G. M. Khandaker, “Inflammation and immunity in schizophrenia : implications for pathophysiology and treatment,” PMC, vol. 2, no. 3, pp. 258–270, 2015, doi: 10.1016/S2215-0366(14)00122-9.Inflammation.
Benjamin James Sadock and MD and Virginia Alcott Sadock, Kaplan and Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 10th edition. USA: Indian J Psychiatry, 2009.
Adam Daniel Zavodnick and Rizwan Ali, “N-Acetylcysteine and Metabotropic Glutamate Receptors: Implications for the Treatment of Schizophrenia: A Literature review,” Natl. Libr. Med., vol. 85, no. 2, pp. 177–85, 2014, doi: 10.1007/s11126-013-9281-3.
Alan Breier, Emily Liffick, Tom A Hummer, Jenifer L Vohs, and Z. Yang, “Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders,” Elsevier, vol. 199, pp. 395–402, 2018, doi: https://doi.org/10.1016/j.schres.2018.03.012.
Š. Šalamon, B. Kramar, T. P. Marolt, and B. Poljšak, “Medical and Dietary Uses of N-Acetylcysteine,” MDPI, vol. 8, no. 5, pp. 1–16, 2019, doi: 10.3390/antiox8050111.
E. M. S. Ian B Hickie, F. I. no Shane P Cross, Tracey A Davenport, A. J. Guastella, and Sharon L Naismith, “Right care, fi rst time:,” J. Aust. Med. Assoc., vol. 211, no. 9, pp. 1–52, 2019, doi: 10.1001/jamapsychiatry.2019.2360.
M. . Tahir Rahman and M. D. John Lauriello, “Schizophrenia: An Overview,” Focus (Madison)., vol. 14, no. 3, pp. 300–307, 2016, doi: 10.1176/appi.focus.20160006.
DOI: https://doi.org/10.35730/jk.v13i2.742
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.